Treatment Options From 5 Experts for Patients With Lung Cancer

Did you recently receive a diagnosis of lung cancer? CCO has developed an Interactive Decision Support Tool to help you understand more about your disease and treatment options. Answer these multiple choice questions about your diagnosis and see treatment plans from 5 lung cancer experts.

Share

Program Content

Activities

NSCLC Patient Tool
Treatment Options From 5 Experts for People With Unresectable Stage III or Metastatic NSCLC: An Online Tool
Tool
Congratulations: You achieved a completion on 04/09/2022

Released: October 02, 2020

Expires: October 01, 2021

Activities

NSCLC Consultation Checklist
Patient-Focused Interactive Treatment Tool: Key Information You Need to Know About Your Advanced NSCLC Diagnosis
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: October 02, 2020

Expires: October 01, 2021

Faculty

cover img faculity

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

cover img faculity

Leora Horn, MD, MSc

Assistant Professor, Hematology Oncology/Medicine
Vanderbilt Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee

cover img faculity

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

cover img faculity

Melissa L. Johnson, MD

Assistant Professor
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center 
Northwestern University
Assistant Attending
Divison of Hematology/Oncology
Northwestern Memorial Hospital
Chicago, Illinois

cover img faculity

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Celgene

Loxo Oncology subsidiary of Eli Lilly

Partners

GRACE

ProCE Banner